$LTRN
Lantern Pharma Inc

2023 Q3 Form 10-Q Financial Statement

#000149315223027345 Filed on August 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.310M $1.632M $1.406M
YoY Change -9.21% 16.08% 6.99%
% of Gross Profit
Research & Development $2.210M $3.558M $2.989M
YoY Change 214.67% 19.05% 156.58%
% of Gross Profit
Depreciation & Amortization $0.00 $3.510K $2.380K
YoY Change -100.0% 47.48% -18.49%
% of Gross Profit
Operating Expenses $3.524M $5.190M $4.395M
YoY Change 64.25% 18.1% 77.28%
Operating Profit -$3.524M -$5.190M -$4.395M
YoY Change 64.25% 18.1% 77.28%
Interest Expense $250.0K $117.8K $55.03K
YoY Change 378.74% 114.1% 4.6%
% of Operating Profit
Other Income/Expense, Net $115.8K $326.1K -$152.6K
YoY Change -167.45% -313.69% -233.01%
Pretax Income -$3.160M -$4.746M -$4.492M
YoY Change 39.53% 5.65% 93.93%
Income Tax
% Of Pretax Income
Net Earnings -$3.161M -$4.746M -$4.492M
YoY Change 39.6% 5.65% 93.93%
Net Earnings / Revenue
Basic Earnings Per Share -$0.29 -$0.44 -$0.41
Diluted Earnings Per Share -$0.29 -$0.44 -$414.8K
COMMON SHARES
Basic Shares Outstanding 10.87M shares 10.86M shares 10.83M shares
Diluted Shares Outstanding 10.86M shares 10.86M shares 10.83M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $44.93M $47.95M $62.15M
YoY Change -22.3% -22.85% -21.91%
Cash & Equivalents $25.57M $28.42M $43.36M
Short-Term Investments $19.35M $19.53M $18.79M
Other Short-Term Assets $2.500M $3.093M $3.513M
YoY Change -40.38% -11.97% 38.19%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $47.43M $51.04M $65.66M
YoY Change -23.53% -22.27% -20.05%
LONG-TERM ASSETS
Property, Plant & Equipment $51.02K $49.95K $40.05K
YoY Change 16.45% 24.73% -85.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $25.87K $25.87K $17.89K
YoY Change 44.61% 44.61% -0.01%
Total Long-Term Assets $345.5K $384.1K $716.8K
YoY Change 138.92% -46.42% 138.15%
TOTAL ASSETS
Total Short-Term Assets $47.43M $51.04M $65.66M
Total Long-Term Assets $345.5K $384.1K $716.8K
Total Assets $47.77M $51.43M $66.38M
YoY Change -23.15% -22.53% -19.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.090M $2.853M $5.174M
YoY Change -31.41% -44.86% 373.0%
Accrued Expenses $170.0K $163.2K $130.7K
YoY Change 84.74% 24.82% -10.41%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.253M $3.016M $5.304M
YoY Change -28.22% -43.14% 97.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $110.0K $150.7K $0.00
YoY Change -100.0%
Total Long-Term Liabilities $110.0K $150.7K $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.253M $3.016M $5.304M
Total Long-Term Liabilities $110.0K $150.7K $0.00
Total Liabilities $2.360M $3.167M $5.304M
YoY Change -24.82% -40.3% 88.17%
SHAREHOLDERS EQUITY
Retained Earnings -$51.06M -$47.90M -$33.64M
YoY Change 42.22% 42.39%
Common Stock $1.087K $1.087K $1.083K
YoY Change 0.09% 0.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $45.41M $48.26M $61.08M
YoY Change
Total Liabilities & Shareholders Equity $47.77M $51.43M $66.38M
YoY Change -23.15% -22.53% -19.47%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$3.161M -$4.746M -$4.492M
YoY Change 39.6% 5.65% 93.93%
Depreciation, Depletion And Amortization $0.00 $3.510K $2.380K
YoY Change -100.0% 47.48% -18.49%
Cash From Operating Activities -$3.610M -$3.592M -$2.733M
YoY Change -10.61% 31.45% 57.96%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$14.18K
YoY Change -100.0% -100.0% 18.07%
Acquisitions
YoY Change
Other Investing Activities $240.0K -$457.2K -$511.6K
YoY Change -454.77% -10.62% -97.2%
Cash From Investing Activities $230.0K -$457.2K -$525.7K
YoY Change -409.31% -13.03% -97.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -3.610M -3.592M -2.733M
Cash From Investing Activities 230.0K -457.2K -525.7K
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash -3.380M -4.049M -3.258M
YoY Change -17.81% 24.27% -83.73%
FREE CASH FLOW
Cash From Operating Activities -$3.610M -$3.592M -$2.733M
Capital Expenditures $0.00 $0.00 -$14.18K
Free Cash Flow -$3.610M -$3.592M -$2.718M
YoY Change -10.46% 32.13% 58.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001763950
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
LTRN Proceeds From Stock Option And Warrant Exercises
ProceedsFromStockOptionAndWarrantExercises
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
LTRN Remeasurement Of Operating Lease Rightofuse Asset And Operating Lease Liability
RemeasurementOfOperatingLeaseRightofuseAssetAndOperatingLeaseLiability
usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2022Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
usd
CY2023Q2 us-gaap Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
Lantern Pharma Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity File Number
EntityFileNumber
001-39318
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-3973463
dei Entity Address Address Line1
EntityAddressAddressLine1
1920 McKinney Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
7th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Dallas
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
75201
dei City Area Code
CityAreaCode
(972)
dei Local Phone Number
LocalPhoneNumber
277-1136
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
LTRN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10869040 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28423170 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37201786 usd
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
541180 usd
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
541180 usd
CY2023Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
19525798 usd
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
17994299 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2551802 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2985472 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
51041950 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
58722737 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
49954 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
48008 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
308251 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
47687 usd
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
25869 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
17889 usd
CY2023Q2 us-gaap Assets
Assets
51426024 usd
CY2022Q4 us-gaap Assets
Assets
58836321 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2852835 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2745407 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
163146 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
52890 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3015981 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2798297 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
150713 usd
CY2023Q2 us-gaap Liabilities
Liabilities
3166694 usd
CY2022Q4 us-gaap Liabilities
Liabilities
2798297 usd
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10869040 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10869040 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10857040 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10857040 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
1087 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1086 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
96417113 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
95691194 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-261837 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-371386 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47897033 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-39282870 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
48259330 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
56038024 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
51426024 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58836321 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1632080 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1405998 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3365401 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2812158 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3558217 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2988823 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6111164 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5649060 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
5190297 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
4394821 usd
us-gaap Operating Expenses
OperatingExpenses
9476565 usd
us-gaap Operating Expenses
OperatingExpenses
8461218 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5190297 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4394821 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-9476565 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-8461218 usd
CY2023Q2 us-gaap Interest Income Other
InterestIncomeOther
117823 usd
CY2022Q2 us-gaap Interest Income Other
InterestIncomeOther
55026 usd
us-gaap Interest Income Other
InterestIncomeOther
251605 usd
us-gaap Interest Income Other
InterestIncomeOther
77447 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
326076 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-152591 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
610797 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-230389 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4746398 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4492386 usd
us-gaap Net Income Loss
NetIncomeLoss
-8614163 usd
us-gaap Net Income Loss
NetIncomeLoss
-8614160 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10857040 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10857040 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10830947 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10830947 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10857040 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10857040 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10853238 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10853238 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10857040 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10830947 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10857040 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10853238 shares
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4746398 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4492386 usd
us-gaap Net Income Loss
NetIncomeLoss
-8614163 usd
us-gaap Net Income Loss
NetIncomeLoss
-8614160 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
33763 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-63783 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
84536 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-276271 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
4077 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
26771 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
25013 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
20479 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
37840 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-37012 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
109549 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-255792 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4708558 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4529398 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8504614 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8869952 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
71571420 usd
CY2022Q1 LTRN Stock Issued During Period Value Common Stock Issued From Warrant And Option Exercises
StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises
299788 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
267004 usd
CY2022Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
2482286 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4121774 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-218780 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
65315372 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
289533 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4492386 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-37012 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
61075507 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
56038024 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
333530 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3867765 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
71709 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
52575498 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
52575498 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
392390 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4746398 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
37840 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
37840 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
48259330 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
48259330 usd
us-gaap Net Income Loss
NetIncomeLoss
-8614163 usd
us-gaap Net Income Loss
NetIncomeLoss
-8614160 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6929 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4374 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
80272 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
72300 usd
us-gaap Share Based Compensation
ShareBasedCompensation
725920 usd
us-gaap Share Based Compensation
ShareBasedCompensation
556537 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
86578 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-67510 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-50633 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-63987 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
-60909 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
-48690 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
12050 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-357100 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-415114 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1562090 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
111774 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3023686 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-79867 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-78298 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
7980 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7349087 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6060364 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8876 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14178 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5909244 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
2004731 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
4500000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1669680 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1418120 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-349229 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2482286 usd
LTRN Proceeds From Stock Option And Warrant Exercises
ProceedsFromStockOptionAndWarrantExercises
299788 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2182498 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-11409 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-28156 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8778616 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8620247 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
37742966 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
52524295 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28964350 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
43904048 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28423170 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43362868 usd
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
541180 usd
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
541180 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28964350 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
43904048 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
141989 usd
LTRN Remeasurement Of Operating Lease Rightofuse Asset And Operating Lease Liability
RemeasurementOfOperatingLeaseRightofuseAssetAndOperatingLeaseLiability
198847 usd
us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
84536 usd
us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
-276271 usd
us-gaap Net Income Loss
NetIncomeLoss
-8614000 usd
us-gaap Net Income Loss
NetIncomeLoss
-8614000 usd
CY2023Q2 LTRN Working Capital
WorkingCapital
48026000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_844_eus-gaap--UseOfEstimates_zI6WXQZAfAM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_z5AHNtNXoLCe">Use of Estimates and Assumptions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The significant areas of estimation include determining research and development accruals, the inputs in determining the fair value of equity-based awards and warrants issued, the inputs in determining present value of lease payments, and determining the fair value of marketable securities. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zMjSbLBnv52j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zsH8P3AJNr6k">Risks and Uncertainties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. Operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including the potential risk of business failure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our marketable securities have had and may in the future have their market value fluctuate due to rises or falls in interest rates. While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are federally insured. Interest bearing and non-interest bearing accounts we hold at these banking institutions are guaranteed by the Federal Deposit Insurance Corporation (“FDIC”) up to $<span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_pid_c20230630__srt--RangeAxis__srt--MaximumMember_z2V86YAFPBY2" title="Cash FDIC insured amount">250,000</span> per depositor, per FDIC-insured bank, per ownership category. Substantially all of our cash balances held at banking institutions at June 30, 2023 are in excess of FDIC coverage.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
LTRN Operating Lease Liability Amortization Expense
OperatingLeaseLiabilityAmortizationExpense
-79867 usd
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
25394000 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
1271000 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
308251 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
313859 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
47687 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
52890 usd
LTRN Remeasurement Of Operating Lease Rightofuse Asset
RemeasurementOfOperatingLeaseRightofuseAsset
198847 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
308251 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
47687 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
163146 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
52890 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
150713 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
313859 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
52890 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
89734 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
184532 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
62448 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
336714 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
22855 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
313859 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
163146 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
150713 usd
LTRN Lease Expiration Date
LeaseExpirationDate
The lease terms were set to expire in April 2023, subject to
LTRN Remeasurement Of Operating Lease Liability
RemeasurementOfOperatingLeaseLiability
198847 usd
LTRN Operating Lease Rightofuse Asset Acquired
OperatingLeaseRightofuseAssetAcquired
141989 usd
LTRN Operating Lease Liability Acquired
OperatingLeaseLiabilityAcquired
141989 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
80272 usd
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M21D
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M29D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0736 pure
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0465 pure
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
67000 usd
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
39000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
109000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
78000 usd
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
5000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
5000 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
72000 usd
CY2022Q2 us-gaap Lease Cost
LeaseCost
39000 usd
us-gaap Lease Cost
LeaseCost
114000 usd
us-gaap Lease Cost
LeaseCost
78000 usd
CY2023Q2 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
12000 shares
us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
12000 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
63000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
63000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10869040 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10869040 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10857040 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10857040 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1037591 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
70000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.92
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
29123 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
10.00
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1078468 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.26
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
20391594 usd
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
59 usd
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
865855 usd
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
19525798 usd
CY2023Q2 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
12021718 usd
CY2023Q2 LTRN Available For Sale Securities Debt Maturities Rolling Year One Through Two Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue
2039232 usd
CY2023Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
14060950 usd
CY2023Q2 LTRN Debt Securities Available For Sale Fair Value Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss
7222538 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
84405 usd
CY2023Q2 LTRN Debt Securities Available For Sale Continuous Fair Value Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss
12007382 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
781450 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
29525798 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1268466 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1117938 shares

Files In Submission

Name View Source Status
0001493152-23-027345-index-headers.html Edgar Link pending
0001493152-23-027345-index.html Edgar Link pending
0001493152-23-027345.txt Edgar Link pending
0001493152-23-027345-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
ltrn-20230630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ltrn-20230630_cal.xml Edgar Link unprocessable
ltrn-20230630_def.xml Edgar Link unprocessable
ltrn-20230630_lab.xml Edgar Link unprocessable
ltrn-20230630_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending